Filtered By:
Drug: Dexamethasone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 6433 results found since Jan 2013.
Second-line tests in the differential diagnosis of neoplastic and non-neoplastic hypercortisolism: a systematic review and meta-analysis
DiscussionBoth Dex-CRH and Desmopressin tests can be valid tools in helping discrimination between NNH/pCS and CS. Further studies are needed on this topic, possibly focusing on mild Cushing ’s Disease and well-characterized NNH/pCS patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022359774, identifier CRD42022359774.
Source: Journal of Endocrinological Investigation - September 22, 2023 Category: Endocrinology Source Type: research
In vitro, in vivo, and in silico evaluation of the glucocorticoid receptor antagonist activity of 3,6-dibromocarbazole
Food Chem Toxicol. 2023 Sep 19:114048. doi: 10.1016/j.fct.2023.114048. Online ahead of print.ABSTRACT3,6-Dibromocarbazole is a novel environmental contaminant which is currently detected in several environmental media worldwide. This work aims to investigate the anti-glucocorticoid potency and endocrine disrupting effects of 3,6-dibromocarbazole. In vitro experiments indicated that 3,6-dibromocarbazole possessed glucocorticoid receptor (GR) antagonistic activity and inhibited dexamethasone-induced GR nuclear translocation. 3,6-Dibromocarbazole reduced the expression levels of glucocorticoid responsive genes including gluco...
Source: Food and Chemical Toxicology - September 21, 2023 Category: Food Science Authors: Haoyang Zou Jia Yu Zhuolin Li Yao Liu Tuoyi Wang Tiezhu Li Chengyu Lv Jie Zhang Source Type: research
Fraxin in Combination with Dexamethasone Attenuates LPS-Induced Liver and Heart Injury and Their Anticytokine Activity in Mice
CONCLUSIONS: All interventions used in this study significantly reduced interleukin-8 (IL-8) levels and reduced LPS-induced liver and cardiac damage. The combination (FD) did not result in an evident superiority of either agent. More research is required to identify the possible usefulness of these agents in treating hyperinflammatory diseases, such as cytokine storms, in future clinical practice.PMID:37727368 | PMC:PMC10506875 | DOI:10.1155/2023/5536933
Source: Adv Data - September 20, 2023 Category: Epidemiology Authors: Nada Sahib Shaker Hayder Bahaa Sahib Source Type: research
Diosgenin prevents dexamethasone-induced myotube atrophy in C2C12 cells
Arch Biochem Biophys. 2023 Sep 16:109759. doi: 10.1016/j.abb.2023.109759. Online ahead of print.ABSTRACTSeveral pathophysiological abnormalities, including a sedentary lifestyle, chronic diseases, and oxidative stress, can contribute to muscle atrophy triggered by an imbalance in muscle protein synthesis and degradation. Resolving muscle atrophy is a critical issue as it can reduce the quality of life. Here, one of the promising functional food factors, diosgenin (a steroidal sapogenin) showed strong preventive activities against dexamethasone (Dex)-induced muscle atrophy, as determined by the expression levels and morphol...
Source: Archives of Biochemistry and Biophysics - September 18, 2023 Category: Biochemistry Authors: Yasukiyo Yoshioka Shiori Oishi Keita Onoda Katsumi Shibata Noriyuki Miyoshi Source Type: research
Treatments for COVID-19
Annu Rev Med. 2023 Sep 18. doi: 10.1146/annurev-med-052422-020316. Online ahead of print.ABSTRACTThe treatment for COVID-19 has evolved rapidly since the start of the pandemic and now consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir and nirmatrelvir-ritonavir, have proved to be most useful earlier in illness (e.g., as outpatient therapy) and for less severe disease. Immunomodulatory therapy, such as dexamethasone and interleukin-6 or Janus kinase inhibitors, are most useful in severe disease or critical illness. The role of anti-SARS-CoV-2 monoclonal antibodies has diminished because...
Source: Annual Review of Medicine - September 18, 2023 Category: General Medicine Authors: Hayden S Andrews Jonathan D Herman Rajesh T Gandhi Source Type: research
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia
Biochem Pharmacol. 2023 Sep 15:115809. doi: 10.1016/j.bcp.2023.115809. Online ahead of print.ABSTRACTAlthough a great cure rate has been achieved for pediatric BCP-ALL, approximately 15% of patients do not respond to conventional chemotherapy and experience disease relapse. A major effort to improve the cure rates by treatment intensification would result in an undesirable increase in treatment-related toxicity and mortality, raising the need to identify novel therapeutic approaches. High-throughput (HTP) drug screening enables the profiling of patients' responses in vitro and allows the repurposing of compounds currently ...
Source: Biochemical Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Athanasios Oikonomou Luigia Valsecchi Manuel Quadri Titus Watrin Katerina Scharov Simona Procopio Jia-Wey Tu Melina Vogt Angela Maria Savino Daniela Silvestri Maria Grazia Valsecchi Andrea Biondi Arndt Borkhardt Sanil Bhatia Giovanni Cazzaniga Grazia Fazi Source Type: research
Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase
CONCLUSION: This analysis revealed that fosnetupitant could have long-acting antiemetic potency (> 120 h) and indicated the importance of antiemetic therapy at 0-120 h for CINV up to 168 h after chemotherapy.PMID:37715851 | DOI:10.1007/s12325-023-02648-1
Source: Adv Data - September 16, 2023 Category: Epidemiology Authors: Naoki Inui Yukihiro Toi Yasuto Yoneshima Masahiro Morise Akito Hata Kaoru Kubota Toshiaki Saeki Tomohide Tamura Source Type: research
Safety of antenatal predniso(lo)ne and dexamethasone on fetal, neonatal and childhood outcomes: a systematic review
CONCLUSIONS: Based on the limited evidence found in this systematic review, predniso(lo)ne may have less side-effects compared to dexamethasone in short- and long-term outcomes. Current literature shows minimal risk of side-effects in the newborn by administration of a prenatal predniso(lo)ne dose of up to 10 mg per day.PMID:37715964 | DOI:10.1210/clinem/dgad547
Source: The Journal of Clinical Endocrinology and Metabolism - September 16, 2023 Category: Endocrinology Authors: Elise M A Slob Jacqueline U M Termote Janna W Nijkamp Hetty J Van der Kamp Erica L T van den Akker Source Type: research
The Local Route of Administration of Dexamethasone in Impacted Mandibular Third Molar Surgery: A Systematic Review and Meta-analysis of Randomised Controlled Trials and a Critical Narrative Review on the Claimed Advantages of the Local Route
ConclusionThe claimed advantages of the local route of DXM do not appear to be scientifically valid. Clinical trials supported with DXM plasma measurements are needed to confirm the absence of a systemic effect when DXM is administered locally.
Source: Journal of Maxillofacial and Oral Surgery - September 16, 2023 Category: ENT & OMF Source Type: research
